WINTON GROUP Ltd Purchases New Stake in ANI Pharmaceuticals, Inc. $ANIP

WINTON GROUP Ltd acquired a new position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 55,058 shares of the specialty pharmaceutical company’s stock, valued at approximately $4,558,000.

Several other hedge funds have also added to or reduced their stakes in ANIP. Corient Private Wealth LP boosted its stake in ANI Pharmaceuticals by 95.2% in the second quarter. Corient Private Wealth LP now owns 24,106 shares of the specialty pharmaceutical company’s stock valued at $1,995,000 after acquiring an additional 11,754 shares during the last quarter. Amundi raised its holdings in shares of ANI Pharmaceuticals by 595.5% in the 2nd quarter. Amundi now owns 31,793 shares of the specialty pharmaceutical company’s stock worth $2,632,000 after purchasing an additional 27,222 shares during the period. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in ANI Pharmaceuticals in the second quarter valued at approximately $1,449,000. California State Teachers Retirement System lifted its stake in ANI Pharmaceuticals by 7,977.4% in the second quarter. California State Teachers Retirement System now owns 1,983,574 shares of the specialty pharmaceutical company’s stock valued at $164,200,000 after purchasing an additional 1,959,017 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in ANI Pharmaceuticals during the second quarter valued at $724,000. Institutional investors own 76.05% of the company’s stock.

Analysts Set New Price Targets

ANIP has been the subject of a number of recent research reports. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Guggenheim cut their price target on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating for the company in a research note on Monday, August 10th. Leerink Partners assumed coverage on ANI Pharmaceuticals in a report on Wednesday. They issued an “outperform” rating and a $104.00 price objective for the company. Wall Street Zen cut ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings downgraded shares of ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a report on Tuesday, August 11th. Five investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $105.57.

Insider Buying and Selling

In other ANI Pharmaceuticals news, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the completion of the transaction, the senior vice president owned 75,534 shares of the company’s stock, valued at $5,816,118. The trade was a 4.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, VP Meredith Cook sold 500 shares of the company’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total value of $37,740.00. Following the sale, the vice president owned 74,424 shares in the company, valued at approximately $5,617,523.52. This represents a 0.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 21,425 shares of company stock worth $1,687,370. Company insiders own 8.10% of the company’s stock.

ANI Pharmaceuticals Stock Up 1.1%

ANI Pharmaceuticals stock opened at $71.46 on Friday. The firm has a 50 day simple moving average of $77.58 and a 200 day simple moving average of $78.25. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. ANI Pharmaceuticals, Inc. has a 1-year low of $69.96 and a 1-year high of $99.39. The firm has a market capitalization of $1.64 billion, a price-to-earnings ratio of 15.40 and a beta of 0.45.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The firm had revenue of $266.04 million for the quarter, compared to the consensus estimate of $260.13 million. During the same quarter in the prior year, the business posted $1.80 earnings per share. The business’s quarterly revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.